🇺🇸 FDA
Company

Cartesian

Cartesian Therapeutics

RNAC pharma USA

Quick answer

Cartesian is a pharma company (RNAC) headquartered in FREDERICK, MD, USA with 11 tracked pipeline programs.

Pipeline (11)

project

Decartes-08

Myasthaenia Gravis

Phase 3 · mab · active

1 trials project

Descartes 08

Myeloma Multiple

Phase 2 · mab · terminated

1 trials project

Descartes-08

Childhood-onset Systemic Lupus Erythematous

Phase 2 · small_molecule · active

1 trials project

Descartes-08

Myasthenia Gravis, Generalized

Phase 2 · small_molecule · active

1 trials project

Descartes-08

Antisynthetase Syndrome

Phase 2 · small_molecule · active

1 trials project

Descartes-08

Systemic Lupus Erythematosus (SLE)

Phase 2 · small_molecule · active

1 trials project

Descartes-11

Multiple Myeloma

Phase 2 · mab · terminated

2 trials project

Descartes 30

Acute Respiratory Distress Syndrome

Phase 1 · mab · terminated

1 trials project

Descartes-08

Multiple Myeloma

Phase 1 · mab · terminated

1 trials project

Descartes-15

Refractory Multiple Myeloma

Phase 1 · small_molecule · terminated

1 trials project

Descartes-25

Multiple Myeloma

Phase 1 · small_molecule · terminated

1 trials

Patents (4)

patent

US 12194078

Methods and compositions related to combined treatment with anti-inflammatories

Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11999773

Anti-BCMA chimeric antigen receptors

Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11220535

Anti-BCMA chimeric antigen receptors

Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10934337

Anti-BCMA chimeric antigen receptors

Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)